Skip to main content
TG THERAPEUTICS, INC. logo

TG THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · TGTX ISIN · US88322Q1085 LEI · 529900X21UKABN9NJ529 US Manufacturing
Open in API
Filings indexed 1,012 across all filing types
Latest filing 2018-09-17 Regulatory Filings
Country US United States of America
Listing US TGTX

About TG THERAPEUTICS, INC.

https://www.tgtherapeutics.com/

TG Therapeutics, Inc. is a fully integrated, commercial-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. The company's primary area of focus is autoimmune diseases, particularly multiple sclerosis (MS). Its lead commercial product is BRIUMVI® (ublituximab), an approved therapy for adults with relapsing forms of MS. TG Therapeutics also develops a pipeline of potential therapies for B-cell malignancies and other autoimmune conditions, including investigational CAR-T cell therapies.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2018
Regulatory Filings
2018-09-17 English
10-Q
Interim / Quarterly Report Q2 2018
2018-08-09 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 7, 2018, by TG Therapeutics, Inc. It announces the results of operations for the second quarter ended June 30, 2018, and mentions a press release and an investor conference call to discuss the financial results and business outlook. The document itself is short (2864 characters) and primarily serves to announce the earnings results and the upcoming call, with the press release attached as an exhibit. This fits the definition of an Earnings Release (ER) as it is the initial announcement of quarterly financial results with key highlights. It is not a full quarterly report (IR) or annual report (10-K), nor is it a regulatory filing or report publication announcement. Therefore, the correct classification is Earnings Release (ER).
2018-08-07 English
Regulatory Filings 2018
Regulatory Filings
2018-07-24 English
Regulatory Filings 2018
Regulatory Filings Classification · 100% confidence The document is a letter addressed to the SEC requesting acceleration of the effective date for a Registration Statement on Form S-3. It references the Securities Act of 1933 and Rule 461, which relate to securities registration and offering processes. The content is procedural and pertains to the filing process rather than containing financial data or report content. The document length is short (1796 characters), and it is clearly an official correspondence related to a regulatory filing. Therefore, it is not an annual report, earnings release, or any financial report but rather a regulatory filing related to securities registration. According to the rules, such correspondence is classified as Regulatory Filings (RNS).
2018-07-18 English
Regulatory Filings 2018
Regulatory Filings
2018-07-17 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.